SENSEX    44149.72       -110.02    |    NIFTY    12968.95       -18.05 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
COMMODITIES
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Stock Alert
Overall view of all the recent market developments which will help in your investment decisions
RIL, Gland Pharma, Mphasis to be watched
20-Nov-20   08:26 Hrs IST

Reliance Industries (RIL) and Reliance Retail Ventures (RRVL) have completed the current phase of partner induction and fund raise exercise for RRVL. RRVL has received cumulative subscription amount of Rs 47,265 crore from various financial partners and allotted 69,27,81,234 equity shares to them.

Shares of Gland Pharma will debut on bourses today, 20 November 2020. Gland Pharma's public issue was open during November 9-11, with a price band of Rs 1,490-1,500 per share.

Mphasis announced its acquisition of Datalytyx, a leading next-gen data engineering and consultancy company. Headquartered in London, United Kingdom, Datalytyx provides Next-gen Data Engineering, Data Ops and Master Data Management solutions on Snowflake and Talend environments to clients globally.

Shares of Vodafone Idea and Bharti Infratel will be in focus. In relation to the merger of Indus Tower (Indus) with Bharti Infratel (Infratel), Vodafone Idea has sold its 11.15% stake in Indus for a cash consideration of Rs. 37.6 billion in accordance with the terms of the agreement and out of the consideration received from Infratel, the company has made a prepayment of Rs 24 billion which will be adjusted in line with terms of the agreement.

Pricol said that the rights issue committee fixed the record date for the purpose of determining the shareholders who will be eligible to apply in the rights issue as 25th November 2020.

Syngene International and Deerfield Discovery and Development Corporation (3DC), the drug discovery and development subsidiary of Deerfield Management Company (Deerfield), have signed an agreement to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation.

Powered by Capital Market - Live News

Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.89 87.81 1.19
United Kingdom (GBP) 1.12 1.00 98.48 1.34
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.84 0.75 73.70 1.00
Commodities << ALL Commodities
GOLDAHMD48778-187
SILVERAHMD59990-268
CRUDEOILMUMBAI34140
COPPERMUMBAI58013.20
 Market News << ALL News
   Attention Investor: Prevent unauthorized transactions in your trading / Demat account : Update your mobile number / e mail ids with your stock broker / deposit." | "No need to issue cheques by investors while subscribing to IPO.Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account." | "KYC is one time exercise while dealing in securities markets- once KYC is done through a SEBI registered intermediary(broker, DP, Mutual Fund etc.) you need not undergo the same process again when you approach another intermediary."
    Disclaimer    |    BSE Disclosure   |    Privacy Policy    |    Investor Protection    |
    Inactive Account    |  Vernacular Language: NSE | BSE
Feedback   |   PMLA Policy   |   Risk Management Policy   |   Insider Trading   
  
   Investor Grivenances   |   Investor Complaints   |   Rules And Regulations   |   Broker Norms   |   Terms of Use SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)